54.85 -0.03 (-0.05%)
After hours: 4:01PM EDT
|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||54.75 - 55.00|
|52 Week Range||47.18 - 58.90|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.11%|
Localized geopolitical risks like the tension in the Middle East are unlikely to cause substantial damage to the markets in the long run, though they could bolster oil prices in the short term. The tension in the Korean Peninsula could be the biggest danger to market stability in the long run. As long as the balance is maintained between US interests and North Korea’s ambitions, the status quo is likely to prevail.
Valeant Pharmaceuticals (VRX) is a specialty pharmaceutical company involved in the development, manufacture, and marketing of branded, generic, branded generic as well as over the counter products. Of the seven analysts covering Valeant Pharmaceuticals in February 2018, two analysts have given the stock a “buy” or higher rating. Three analysts have given it a “hold” rating, and two analysts have given the stock a “sell” rating.
What Triggered the Stock Market Panic This Month? The last two trading sessions on February 2 and 5 have left many investors worried about assets in the bond (BND) and stock markets. The sell-off in the stock market began after the US employment report was published on Friday, February 2.
As we saw earlier, Wall Street analysts are estimating that AstraZeneca (AZN) will report EPS (earnings per share) of $0.47 on revenues of $5.4 billion in 4Q17, a 2.5% decline compared to $5.6 billion in 4Q16. AstraZeneca stock has risen 32% over the last 12 months. Analysts’ estimates show that the stock has a potential to return 8.6% over the next 12 months.
In 3Q17, GlaxoSmithKline (GSK) reported revenues close to 298 million pounds from the sale of its meningitis vaccines, which is year-over-year (or YoY) growth of 31% on a reported basis and 25% on a constant exchange rate (or CER) basis. The company’s meningitis vaccines portfolio witnessed sales worth 143 million pounds in the US market in 3Q17, which is YoY growth of 44% on a reported basis and 36% on a CER basis. GlaxoSmithKline earned revenues close to 103 million pounds from the sale of meningitis vaccines in Europe in 3Q17, which is a YoY rise of 34% on a reported basis and 30% on a CER basis.
To maintain its leadership in the chronic obstructive pulmonary disease (or COPD) segment, GlaxoSmithKline (GSK) has focused on shifting patients away from LAMA monotherapy to its LAMA/LABA bronchodilators, Anoro and Incruse. The company also expects to see COPD patients who are at higher risk of exacerbations to shift from open triple therapy to closed triple therapy such as the recently launched Trelegy Ellipta.
In 3Q17, Novo Nordisk’s (NVO) NovoRapid reported revenues of 5.0 billion Danish krone (or DKK), which reflected ~9% growth on year-over-year (or YoY) basis.
While the U.S. stock market is in the midst of its second-longest bull run in history, the real encouragement came from the international stock market.
In 3Q17, Novartis’s Cosentyx generated revenues of $556 million, which reflected a whopping 85% growth YoY (year-over-year) and ~13% growth QoQ.
Why is Vanguard voting against a shareholder measure on its proxy ballot that moves to stop investing in companies that "substantially contribute" to genocide?
In 1H17, Novartis's (NVS) Tafinlar & Mekinist reported revenues of around $403 million, which reflected ~25% growth on a year-over-year (or YoY) basis.
ViiV Healthcare is a global specialist company in HIV medicines. It focuses on developing and delivering advanced treatments for patients with HIV.
Alcon reported revenues of $1.52 billion for 2Q17, which was 1% higher YoY (year-over-year) than the $1.51 billion we saw in 2Q16.
International stocks have been the real winners this year courtesy of cheap valuations and improving economic growth in many parts of the world.